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Abstract Macrophage migration inhibitory factor (MIF)
is a critical inflammatory cytokine that was recently asso-
ciated with progenitor cell survival and potently inhibits
apoptosis. We examined the protective effect of MIF on
hypoxia/serum deprivation (SD)-induced apoptosis of
mesenchymal stem cells (MSCs), as well as the possible
mechanisms. MSCs were obtained from rat bone marrow
and cultured in vitro. Apoptosis was induced by culturing
MSCs under hypoxia/SD conditions for up to 24 h and
assessed by flow cytometry. Expression levels of c-Met,
Akt, and FOXO3a were detected by Western blotting.
CD74 expression was detected by qRT-PCR, Western blot,
and immunofluorescence. Oxidative stress under hypoxia/
SD was examined by detection of reactive oxygen species
(ROS) and activity of superoxide dismutase (SOD) and
malondialdehyde (MDA). Hypoxia/SD-induced apoptosis
was significantly attenuated by recombinant rat MIF in a
concentration-dependent manner. MIF induced CD74-ass-
sociated c-Met activation, which was blocked by knocking
down CD74 expression using siRNA. MIF also induced
Akt and associated FOXO3a phosphorylation, and this
effect was abolished by knocking down either CD74 or
Akt. In addition, MIF decreased oxidative stress in MSCs,
as shown by decreased ROS and MDA, and increased the
activity of SOD. Knockdown of CD74, Akt, or FOXO3a
largely attenuated the anti-apoptotic effect of MIF and its
ability to protect against oxidative stress. MIF protected
MSCs from hypoxia/SD-induced apoptosis by interacting
with CD74 to stimulate c-Met, leading to downstream
PI3K/Akt-FOXO3a signaling and decreased oxidative
stress.
Keywords Mesenchymal stem cells  Hypoxia/serum
deprivation-induced apoptosis  MIF  PI3K/Akt-FOXO3a
signaling pathways  Oxidative stress
Introduction
In the absence of effective endogenous repair mechanisms
after cardiac injury, cell-based therapies have rapidly
emerged as a potential novel therapeutic approach in is-
chemic heart disease [1]. Allogeneic mesenchymal stem
cells (MSC) are immunoprivileged, easily obtained, and
improved heart function in preclinical and clinical studies,
so have been widely used in the treatment of ischemic
heart diseases [2]. Despite promising results, many prob-
lems, including massive cell death after transplantation,
have limited the efficacy of this cell therapy [3]. At this
stage, further optimization of MSC-based therapy is ur-
gently needed, and growth factors and cytokines, pre-
conditioning, and genetic modification, have all been
manipulated in an attempt to enhance MSC survival [4–
6]. Devising a more effective and accessible pro-survival
strategy may make this therapeutic approach more at-
tractive to the specialist.
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Macrophage migration inhibitory factor (MIF) is a
pleiotropic cytokine expressed in several cell types, in-
cluding monocytes/macrophages, vascular smooth muscle,
and cardiomyocytes [7–9], and serves as a regulatory factor
in inflammation, apoptosis, autophagy, and carbohydrate
metabolism [10–13]. Cell survival and proliferation is in-
duced by MIF under stress conditions such as inflammation
and starvation [11, 14–16]. With respect to apoptosis, MIF
has been shown to act as an anti-apoptotic agent in various
cells [10, 17], and recent research has confirmed that it can
protect neural stem/progenitor cells from apoptosis [10].
Therefore, it is possible that MIF may be involved in a
protective capacity against hypoxia/SD-induced MSC
apoptosis.
CD74 is a well-known receptor for MIF. MIF binds to the
CD74 extracellular domain to activate signaling pathways
which play an anti-apoptotic role in some cells [18]. The
phosphoinositide-3-kinase (PI3K)/Akt signaling pathway,
which can be activated by MIF binding to CD74, functions
in the cellular response to growth factors, and regulates key
cellular functions including growth, metabolism, migration,
apoptosis, and survival [17, 19, 20]. Forkhead transcription
factor FOXO3a, the PI3K/Akt downstream substrate, is a
positive regulator of cell survival in response to a variety of
stress stimuli such as oxidative stress, DNA damage, and
nutrient deprivation [21, 22], and activation of FOXO3a
signaling has been shown to produce an anti-apoptotic effect
in haematopoietic stem cells [19]. It has also been demon-
strated that MIF stimulates the PI3K/Akt-FOXO3a signal-
ing pathway [20], and that the MIF receptor CD74 is
expressed on MSCs [23], in which the related PI3K/Akt-
FOXO3a pathway exerts a protective effect [24, 25]. Thus,
binding of MIF to CD74 and activation of the PI3K/Akt-
FOXO3a pathway may facilitate resistance to hypoxia/SD-
induced apoptosis in MSCs.
Reactive oxygen species (ROS) also play an important
role in apoptosis induction under both physiologic and
pathologic conditions. A previous study showed that ROS
hinder adhesion of implanted MSCs to ischemic my-
ocardium, resulting in apoptosis [26]. MIF not only func-
tions primarily as a proinflammatory cytokine but also
exhibits anti-oxidant properties by virtue of its intrinsic
oxidoreductase activity [27]. Previous studies have con-
firmed that MIF protects cells from apoptosis by inhibiting
ROS generation [28] and it is possible that MIF may pro-
tect MSCs from hypoxia/SD-induced apoptosis via a
similar mechanism.
We hypothesized that exogenous MIF may prevent hy-
poxia/SD-induced apoptosis of MSCs and promote subse-
quent survival of these cells. The present study examined
the effect of MIF on hypoxia/SD-induced apoptosis of
MSCs and its related signaling pathways.
Materials and methods
Animals
Male Sprague–Dawley rats weighing 60–80 g were cared
for in accordance with published guidelines from the U.S.
National Institutes of Health. All study procedures were
approved by the Harbin Medical University Institutional
Animal Care and Use Committee. The study was con-
ducted in compliance with the Guide for the Care and Use
of Laboratory Animals published by the National Academy
Press (NIH, revised 1996).
Reagents
Dulbecco’s modified Eagle’s medium (DMEM) and fetal
bovine serum (FBS) were obtained from Hyclone (Hy-
clone, Logan, UT).Trizol reagent was obtained from In-
vitrogen (Carlsbad, CA). The transcriptor First Strand
cDNA Synthesis Kit, X-treme GENE HP DNA transfection
reagent, and Fast Start Universal SYBR Master (ROX)
were obtained from Roche (Mannheim, Germany). The
annexin V-FITC Apoptosis Detection Kit, anti-CD44, anti-
CD29, and anti-CD90 antibodies were obtained from BD
Pharmingen (Franklin Lakes, NJ, USA). Anti-CD34 and
anti-CD45 antibodies were obtained from eBioscience (San
Diego, CA). Rabbit monoclonal antibodies against Akt,
phospho-Akt (Ser473), phospho-Akt (Tyr308), phospho-
FoxO1 (Thr24)/FoxO3a (Thr32), and FoxO3a were pur-
chased from Cell Signaling Technology (Danvers, MA,
USA). Rabbit monoclonal antibody CD74 was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse
polyclonal b-actin antibody was purchased from Zhong-
shan Goldenbridge Biotechnology (Zhongshan Golden-
bridge Biotechnology Co. Ltd., #TA-09). Horseradish
peroxidase-conjugated secondary antibodies to mouse or
rabbit were obtained from Santa Cruz Biotechnology.
Alexa Fluor 555 goat anti-rabbit IgG was obtained from
Invitrogen. MIF ELISA kit was obtained from Rapidbio
(CA, USA). Small interfering RNA (siRNA) to Akt and
FOXO3a genes was obtained from Life Technologies
(Carlsbad, CA) and siRNA to CD74 was obtained from
QiaGen. Rat recombinant MIF was obtained from Prospec
(NJ, USA). 20,70-dichlorodihydrofluorescein diacetate
(DCF-DA) was obtained from Beyotine Institute of
Biotechnology (Nantong, China). Rabbit monoclonal anti-
body c-Met, lipid peroxidation (MDA) assay kit, and SOD
activity colorimetric assay kit were obtained from Abcam
(Cambridge, UK). 3-(4,5,-Dimethyl thiazolyl-2)-2,5-
diphenyl tetrazolium bromide(MTT) and dimethyl sulfox-
ide (DMSO) were purchased from Sigma-Aldrich (St
Louis, MO, USA).
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Cell culture and treatment
Bone marrow-derived mesenchymal stem cells (BM-
MSCs) were isolated from femurs and tibias of Sprague–
Dawley rats as described previously [29]. Briefly, bone
marrow cells were flushed from femurs and tibias with
5 mL DMEM/F12. After red blood cells were lysed and
removed, 5 9 105 cells were plated in a 25-cm2 flask with
6 mL DMEM/F12 supplemented with 10 % FBS and 1 %
penicillin/streptomycin at 37 C with 5 % CO2. After
3 days in culture, non-adherent cells were washed off with
medium and adherent MSCs were further grown in medium
replaced every 3 days. At 80–90 % confluence, adherent
cells were trypsinized, diluted 1:2–2:3, and re-expanded.
All cells used in each assay were at passages 3–5. The
characteristics of MSCs were demonstrated by im-
munophenotyping as described previously [29].
For MIF stimulation, cells were refreshed with medium
containing 100 ng/mL of recombinant MIF and incubated at
37 C for various periods as previously reported [17]. In-
duction of apoptosis in vitro by hypoxia and serum depriva-
tion (hypoxia/SD), designed to mimic the in vivo conditions
of ischemicmyocardium, was initiated as previously reported
[30]. Apoptosis was induced by incubating MSCs in serum-
free media in a controlled atmosphere (anaerobic chamber)
glove box (Plas Labs 855-AC) to scavenge free oxygen. MIF
(100 ng/mL) was added to the medium at the beginning of
hypoxia/SD exposure and incubation was continued for 24 h
under hypoxic conditions. Cells exposed to hypoxia/SD alone
without MIF exposure were used as apoptotic controls.
Flow cytometric analysis of cell apoptosis
Apoptosis was determined by detecting phosphatidylserine
exposure on cell plasmamembranes with the fluorescent dye
Annexin V-FITC Apoptosis Detection Kit, according to
manufacturer’s protocol. This assay discriminates between
intact (Annexin V-/propidium iodide (PI)-, early apoptotic
(Annexin V?/PI-), late apoptotic (Annexin V?/PI?), and
necrotic (Annexin V-/PI?) cells. Briefly, cells were har-
vested and washed in ice-cold PBS, resuspended in 300 lL
binding buffer, and incubated with 5 lL Annexin V-FITC
solution for 30 min at 4 C in dark conditions. This was
followed by a further incubation in 5 lL PI for 5 min and
immediate analysis of the cells by bivariate flow cytometry
using the BD FACSCanto II equipped with BD FACSDiva
Software (Becton–Dickinson, San Jose, CA). Ap-
proximately 1–5 9 105 cells were analyzed in each sample.
MTT assay
We tested the potential toxicity of MIF in cultured MSCs.
The cells were incubated with increasing concentrations of
MIF in culture medium for 24 h. A total of 300 lL of MTT
reagent were added to each well 2 h prior to harvesting.
The supernatant was then removed and incubated with
400 lL of DMSO for 10 min. Absorbance at 540 nm was
recorded using an enzyme-linked immunosorbent assay
plate reader.
ELISA
Secretion of MIF was measured in cell culture media using
an ELISA kit. The assays were conducted in 96-well mi-
croplates according to the manufacturer’s instructions.
Small interfering RNA (siRNA) knockdown
Cells were transfected using X-treme GENE HP DNA
Transfection Reagent, according to the manufacturer’s in-
structions. In brief, MSCs were plated in a 6-well plate and
treated with X-treme GENE HP DNA Transfection
Reagent in a 3:1 ratio of reagent volume (lL) to siRNA
mass (lg) for 20 min. Cells were then transfected with a
mixture containing 100 nM siRNA and incubated in 2 mL
of culture medium for 48 h. Scrambled siRNA (siRNA-
Fig. 1 MSCs produced MIF upon exposure to hypoxia/SD. MSCs
were cultured under hypoxic/SD or normal conditions for 24 h.
(a) MIF mRNA levels were analyzed by qRT-PCR as described in the
methods. (b) Release of MIF was analyzed by ELISA. Each column
represents the mean ± SD of three independent experiments;
*P\ 0.05 versus control
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NT) was used as the control. Transfection efficiency of
siRNA-CD74, siRNA-Akt, and siRNA-FOXO3a was ana-
lyzed by Western blotting of the relevant proteins com-
pared to scrambled siRNA controls.
Real time polymerase chain reaction
Gene expression was analyzed by quantitative real time
polymerase chain reaction (qRT-PCR). Briefly, total RNA
Fig. 2 MIF protected MSCs against hypoxia/SD-induced apoptosis.
MIF (1–1000 ng/mL) was added at the point of exposure to hypoxia/
SD and was maintained in the incubation medium throughout the
hypoxia/SD treatment period. Apoptosis was measured by flow
cytometry. (a) Representative of three FACS can flow cytometric
analyses of apoptotic cells after Annexin V and PI staining. (b) Fold-
changes compared with corresponding control cells. Each column
represents the mean ± SD of three independent experiments.
*P\ 0.05 versus control, Filled triangle P\ 0.05 versus hypoxia/
SD. (c) MIF was added to culture media alone in order to test its
effect on MSC viability, and analyzed for their viability by MTT
assay. The MTT assay indicated that MIF up to 1000 ng/mL was not
toxic to cultured MSCs. Each column represents the mean ± SD of
three independent experiments
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was isolated and reverse transcribed to cDNA using the
transcriptor First Strand cDNA Synthesis Kit according to
the manufacturer’s instructions. qPCR was carried out with
the Fast Start Universal SYBR Master and fluorescence
quantitative PCR system. The threshold cycle was set
within the exponential phase of the PCR. Relative gene
expression was calculated by comparing cycle times for
each target PCR. The target PCR Ct values were normal-
ized by subtracting the GAPDH Ct value, which provided
the 4Ct value. The relative expression level between
treatments was then calculated using the following equa-
tion: relative gene expression = 2-(4Ct sample–4Ct control).
Western blotting analysis
Western blotting experiments were carried out as previously
described [29]. Briefly, cells were washed twice with ice-
cold PBS and ruptured with lysis buffer containing 20 mM
Tris–HCl, 150 mM NaCl, 1 % Triton X-100, and protease
and phosphatase inhibitors. Cell extracts were centrifuged
for 5 min at 12,0009g and supernatantswere collected. In all
experiments, 20 lg of cellular protein was resolved by SDS-
PAGE and transferred onto PVDF membranes. Membranes
were blocked for 1 h with 5 % skim milk in Tris-buffered
saline containing 0.1 %Tween20 and incubated overnight at
Fig. 3 MIF influenced
expression of CD74 in MSCs.
(a, b) Expression of CD74
mRNA (a) analyzed by qRT-
PCR, and protein (b) analyzed
by Western blot. Each column
represents Mean ± SD from
three independent experiments;
P[ 0.05. (c) Densitometric
quantification of CD74
expression relative to internal
control b-actin. (d) Expression
of CD74 on the cell surface of
MSCs was analyzed by
immunofluorescence assay
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4 C with primary antibodies. Membranes were washed,
incubated for 1 h with appropriate secondary antibodies
conjugated to horseradish peroxidase, and developed using
chemiluminescence substrates, photographed with BIO-
RAD ChemiDoc XRS equipment, quantified, and analyzed
with Quantity One software.
Immunofluorescence staining
To investigate the expression of CD74 on the surface of
MSCs, cells were grown on glass coverslips and fixed with
4 % paraformaldehyde for 15 min at room temperature,
blocked with 10 % BSA and incubated with anti-CD74 an-
tibody at 4 C over night. After washing, the cells were in-
cubated with the Alexa Fluor 555-conjugated goat anti-
rabbit IgG for 1 h at 37 C. The nuclei of cells were coun-
terstained with 40,6-diamidino-2-phenylindole. Fluores-
cence images were acquired with a fluorescencemicroscope.
ROS measurement
The level of intracellular ROS was determined using 2,7-
dichlorodihydrofluorescein diacetate (DCFH-DA), follow-
ing the manufacturer’s instructions. The fluorescence in-
tensity of cells was measured with a fluorescence
spectrophotometer, with excitation and emission wave-
lengths of 488 and 525 nm, respectively.
SOD activity
SOD activity was determined in MSCs using a colorimetric
assay kit (Abcam) according to the manufacturer’s proto-
col. Briefly, protein was isolated using lysis buffer from
control and MIF-exposed MSCs and SOD activity was
measured using 10 ug of the total protein extract. Ab-
sorbance values were measured at 450 nm.
Lipid peroxidation assays
Lipid peroxidation was monitored using an assay kit (Abcam)
tomeasure formation ofMDAaccording to themanufacturer’s
protocol. Briefly,MSCs (1 9 106 cells) were homogenized on
ice in 300 ll of MDA Lysis Buffer (with 3 ll BHT (1009),
then centrifuged (13,0009g, 10 min) to remove insoluble
material. Supernatant (200 ll) was added to 600 ll of thio-
barbituric acid and incubated at 95 C for 60 min. The samples
were cooled to room temperature in an ice bath for 10 min, and
absorbance at 532 nm was measured spectrophotometrically.
Statistical analysis
Data were expressed as mean ± SD. Differences among
groups were tested by one-way ANOVA, and comparisons
between two groups were evaluated using Student’s t test
provided by the statistical software SPSS package v19.0
(SPSS, Inc., Chicago, IL, USA). A value of P\ 0.05 was
considered statistically significant.
Results
MSCs produced MIF upon exposure to hypoxia/SD
As a first step, we examined MIF mRNA expression under
hypoxia/SD using qRT-PCR and found that MIF mRNA
level increased approximately fourfold compared with the
normoxic control (Fig. 1a). Moreover, we found that hy-
poxia/SD stimulated MIF release. There was an ap-
proximately fourfold increase in release of MIF into the
medium as compared to control cells in normoxia (Fig. 1b).
MIF protected MSCs from hypoxia/SD-induced
apoptosis
In preliminary experiments, hypoxia/SD induced MSC
apoptosis with a maximal induction of early apoptosis at
24 h [29]. We then asked if MIF could protect MSCs from
hypoxia/SD-induced apoptosis. MSCs were exposed to
various concentrations of MIF (1–1000 ng/mL) followed
by exposure to hypoxia/SD for 24 h. Cell apoptosis was
determined by FACS. The data showed a clear anti-apop-
totic effect of MIF (Fig. 2) as MIF at any concentration
efficiently blocked apoptosis. The extent to which cells
entered apoptosis was examined by monitoring staining
with Annexin V-FITC at the end of the incubation period
(Fig. 2a, b). Results showed that MIF significantly inhib-
ited hypoxia/SD-induced apoptosis, with the most pro-
nounced effects observed at 100–1000 ng/mL (100 ng/mL:
3.04 ± 0.063 vs. 8.12 ± 0.44, P\ 0.05; 1000 ng/mL:
3.17 ± 0.063 vs. 8.12 ± 0.44, P\ 0.05).
bFig. 4 MIF protected MSCs from apoptosis through a MIF/CD74-
related molecular pathway. (a, b) MSCs were transfected with siRNA
against the CD74 transcript or with siRNA-NT as control. siRNA-
mediated transfection efficiency was determined by Western blot.
Each column represents the mean ± SD of three independent
experiments; *P\ 0.05 versus siRNA-CD74. (c, d) MSCs were
incubated under hypoxic/SD conditions for 24 h. In parallel ex-
periments, cells were treated with MIF (100 ng/mL) in the incubation
medium throughout the hypoxia/SD treatment period. Apoptosis was
analyzed by FACS. Each column represents the mean ± SD of three
independent experiments; *P\ 0.05 versus control; Filled triangle
P\ 0.05 versus hypoxia/SD, White circle P\ 0.05 versus hypoxia/
SD ? siRNA-CD74. (e, f) Expression levels of c-Met were analyzed
by Western blot assay. Each column represents the mean ± SD of
three independent experiments; *P\ 0.05 versus control; Filled
triangle P\ 0.05 versus hypoxia/SD, White circle P\ 0.05 versus
hypoxia/SD ? siRNA-CD74
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To assure that MIF was not toxic to MSCs at these
concentrations, we examined toxic effects on cell viability
using an MTT assay. MIF had no adverse effect on the
viability of MSCs at concentrations up to 1000 ng/mL
(Fig. 2c).
MIF protected MSCs from apoptosis through
a MIF-CD74-dependent molecular pathway
Because CD74 is an important receptor for MIF, we tested
if MIF protected MSCs from apoptosis via an interaction
with CD74 by evaluating CD74 expression in hypoxia/SD-
treated MSCs. As shown in Fig. 3a–c, the mRNA and
protein levels of CD74 were the same whether treated with
hypoxia/SD or MIF. We also verified expression of CD74
by immunofluorescent staining (Fig. 3d).
To further confirm the role of CD74 in the MIF anti-
apoptotic effect, we inhibited CD74 expression using
siRNA and examined apoptosis of MSCs under hypoxic/
SD conditions. As shown in Fig. 4a, b, siRNA transfection
significantly decreased the expression of CD74 compared
to control (14.22 ± 3.35 vs. 100.00 ± 0.00 %, P\ 0.05).
Silencing CD74 significantly attenuated the anti-apoptotic
effect of MIF (7.67 ± 0.34 vs. 3.00 ± 0.23, P\ 0.05). In
contrast, no difference was found when MSCs were
transfected with siRNA-NT (3.11 ± 0.11 vs. 3.00 ± 0.23;
Fig. 4c, d).
Because CD74 is known to activate cellular c-Met, we
investigated c-Met expression in MSCs following MIF
exposure. As shown in Fig. 4e, f, MIF treatment increased
expression of c-Met (7.89 ± 0.29 vs. 1.00 ± 0.00,
P\ 0.05) compared to the control. Transfection of MSCs
with siRNA-CD74 abolished the effect of MIF
(2.86 ± 0.19 vs. 7.89 ± 0.29, P\ 0.05; Figs. 4e, f).
MIF protected MSCs from hypoxia/SD-induced
apoptosis through CD74-sensitive PI3K/Akt-FOXO3a
pathways
The PI3K/Akt signaling pathway is an important regulator
promoting survival of many cell types. Therefore, we in-
vestigated whether this pathway mediated the anti-apop-
totic effect of MIF in MSCs. Western blotting analysis
showed low detectable levels of phospho-Akt in control
cells. MIF induced a pronounced increase in Akt phos-
phorylation at two sites (S473: 7.41 ± 0.23 vs.
1.00 ± 0.00, P\ 0.05; T308: 7.73 ± 0.24 vs.
1.00 ± 0.00, P\ 0.05) which was abolished by silencing
CD74 expression (S473: 2.74 ± 0.35 vs. 7.41 ± 0.23,
P\ 0.05; T308: 2.87 ± 0.08 vs. 7.73 ± 0.24, P\ 0.05;
Fig. 5a–d). Downstream from PI3K/Akt, we found that
MIF also induced significant phosphorylation of FOXO3a
(5.00 ± 0.23 vs. 1.00 ± 0.00, P\ 0.05). Silencing Akt
expression with siRNA-Akt (Fig. 5e, f) abolished the effect
of MIF on FOXO3a phosphorylation (2.37 ± 0.33 vs.
5.00 ± 0.23, P\ 0.05; Fig. 5g, h).
To further confirm the role of PI3K/Akt and FOXO3a in
the anti-apoptotic effect of MIF, we silenced Akt and
FOXO3a using siRNA and examined apoptosis of MSCs
under hypoxic/SD conditions. As shown in Fig. 5, knock-
down of Akt or FOXO3a gene expression by siRNA de-
creased the level of Akt and FOXO3a protein to
10.59 ± 0.55 and 14.51 ± 1.13 %, respectively, compared
to control cells. Silencing of either Akt or FOXO3a sig-
nificantly attenuated the anti-apoptotic effect of MIF
(siRNA-Akt: 7.64 ± 0.41 vs. 3.07 ± 0.17, P\ 0.05;
siRNA-FOXO3a: 7.81 ± 0.32 vs. 3.07 ± 0.17, P\ 0.05;
Fig. 6a, b). In contrast, transfection with siRNA-NT did not
alter the anti-apoptotic effect of MIF (3.00 ± 0.34 vs.
3.07 ± 0.17).
MIF showed anti-apoptotic effects via inhibition
of oxidative stress
To determine whether the anti-apoptotic effects of MIF in-
volved oxidative stress under hypoxic/SD conditions, we
examined generation of ROS, activation of SOD, and lipid
peroxidation by MDA assay. MIF increased activation of
SOD (76.22 ± 1.93 vs. 32.48 ± 2.04 %, P\ 0.05), de-
creased generation of ROS (3.07 ± 0.17 vs. 7.37 ± 0.47,
P\ 0.05), and reduced MDA activation (0.31 ± 0.03 vs.
0.83 ± 0.04, P\ 0.05; Fig. 7). siRNAs against CD74, Akt,
or FOXO3a were all potent blockers of MIF inhibition
(Figs. 7a–c).
bFig. 5 MIF-induced activation of the PI3K/Akt-FOXO3a pathway.
(a–d) Representative images of Western blots showing Akt and
phospho-Akt expression. Cells were transfected with siRNA-CD74 or
siRNA-NT before treatment with MIF (100 ng/mL) and incubation in
hypoxic/SD conditions for 24 h. Fold change in phospho-Akt
expression was compared to Akt. Each column represents the
mean ± SD of three independent experiments; *P\ 0.05 versus
control; Filled triangle P\ 0.05 versus hypoxia/SD, White circle
P\ 0.05 versus hypoxia/SD ?siRNA-CD74. (e, f) MSCs were
transfected with siRNA against Akt or with siRNA-NT. The siRNA-
mediated transfection efficiency was determined by Western blotting.
Each column represents the mean ± SD of three independent
experiments; *P\ 0.05 versus siRNA-Akt). (g, h) Representative
images of Western blots of FOXO3a and phospho-FOXO3a. Cells
were transfected with siRNA-Akt or siRNA-NT before treatment with
MIF (100 ng/mL) and incubation under hypoxic/SD conditions for
the indicated time. Fold change in phospho-FOXO3a was compared
to FOXO3a. Each column represents the mean ± SD of three
independent experiments; *P\ 0.05 versus control; Filled triangle
P\ 0.05 versus hypoxia/SD, White circle P\ 0.05 versus hypoxia/
SD ? siRNA-Akt. (i, j) MSCs were transfected with siRNA against
FOXO3a or with siRNA-NT. siRNA-mediated transfection efficiency
was determined by Western blotting. Each column represents the
mean ± SD of three independent experiments; *P\ 0.05 versus
siRNA-FOXO3a
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Fig. 6 MIF protected MSCs from hypoxia/SD-induced apoptosis
through a CD74-sensitive PI3K/Akt-FOXO3a pathway. (a, b) To
determine which kinase pathway was involved in the anti-apoptotic
actions of MIF, MSCs were transfected with siRNA against Akt or
FOXO3a, or with siRNA-NT as a control. MSCs were then incubated
under hypoxic/SD conditions for 24 h. In parallel experiments, cells
were treated with MIF (100 ng/mL) during exposure to hypoxia/SD.
The apoptosis rate was analyzed by flow cytometry. Each column
represents the mean ± SD of three independent experiments;
*P\ 0.05 versus control; Filled triangle P\ 0.05 versus hypoxia/
SD ? MIF, White circle P\ 0.05 versus hypoxia/SD ? siRNA-NT
20 Mol Cell Biochem (2015) 404:11–24
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Discussion
Autologous MSCs offer a great advantage when used to
regenerate and repopulate injured myocardium, restoring
heart function after transplantation into ischemic or in-
farcted heart. AutologousMSCs can be easily prepared from
adult patients and they are immunologically safe [31].
However, the ratio of surviving cells following MSC en-
graftment is extremely low despite the large number of
implanted cells, probably due to a high rate of cell death
induced by the ischemic environment [5, 32], where trans-
planted MSCs encounter nutrient and oxygen deprivation
and oxidative stress. In such a stressful environment, it is
likely that many transplanted cells undergo apoptosis, so
enhancing the survival ofMSCs is a significant challenge for
stem cell-based therapy [24]. In the present study, we show
that the anti-oxidant effect induced by MIF protects MSCs
from hypoxia/SD-induced apoptosis via a CD74-dependent
Akt-FOXO3a-related pathway, likely by enhancing MSC
survival in the face of growth factor fluctuations and nutrient
deprivations that naturally occur in the ischemic microen-
vironment, especially after cardiac infarction.
MIF is an important cytokine mediating anti-oxidant and
stress responses [33]. MIF has diverse enzymatic activities
which reflect its various functions in cells, including par-
ticipation in cell survival, proliferation, and migration [34–
36]. MIF is overexpressed in various stress conditions such
as ischemia, hypoxia, and oxidation, and it exerts an ap-
parent cellular protective effect through repair of DNA
damage, modulation of p53 gene expression, and reduction
in oxidative stress [37, 38].With regard to apoptosis, MIF is
also known to affect signaling in growth and apoptosis-
regulating pathways, and is a powerful anti-apoptotic agent
in various cells [39, 40]. In our investigation, culture of
MSCs under hypoxic/SD conditions-induced MIF gen-
eration, in agreement with previous studies showing that
cellular stress-induced MIF overexpression [9]. In those
studies, insufficient MIF was generated to protect MSCs
from hypoxia/SD-induced apoptosis, but our results
showed that exogenously increasing MIF protected MSCs
from hypoxia/SD-induced apoptosis in a concentration-
dependent manner.
CD74, a type II transmembrane glycoprotein that acts as
an MHC class II chaperone, was previously described as a
cognate ligand for MIF [18]. Subsequent experiments
demonstrated that MIF initiated a signaling cascade which
resulted in cell survival in a CD74-dependent manner [10,
17, 20]. In our experiments, hypoxia/SD or MIF failed to
Fig. 7 MIF exerted anti-
apoptotic effects via inhibition
of oxidative stress. MSCs were
incubated under hypoxic/SD




before exposure to hypoxia/SD.
When used, MIF (100 ng/mL)
was added at the beginning of
exposure to hypoxia/SD.
(a) Intracellular ROS
production in MSCs was
analyzed by fluorescence
spectrophotometer. (b) SOD
activity was evaluated using a
colorimetric assay. (c) MDA
formation was used to evaluate
lipid peroxidation. Each column
represents the mean ± SD of
three independent experiments;
*P\ 0.05 versus control; Filled
triangle P\ 0.05 versus
hypoxia/SD ? MIF, White
circle P\ 0.05 versus hypoxia/
SD ? MIF ? siRNA-NT
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alter expression of CD74, but using siRNA to silence CD74
expression significantly attenuated the anti-apoptotic effect
of MIF, confirming that MIF exerted its anti-apoptotic ef-
fect in a CD74-dependent manner. CD74 does not have a
typical signal-transducing cytosolic domain, but may uti-
lize a signal-transducing coreceptor pathway in which re-
cruitment of CD44 activates non-receptor tyrosine kinases
[18] A previous study demonstrated that stimulation of
CD74 by MIF recruits the tyrosine kinase receptor c-Met to
the CD74/CD44 complex and thereby enables induction of
a signaling cascade within the cell to promote B cell sur-
vival [41]. Activated c-Met triggers a cascade of signal
transduction pathways including activation of PI3K and
Akt, which have been implicated in cell migration, cell
motility, cell cycle progression, and cell survival [42–44].
In our study, MIF-induced c-Met activation, which was
inhibited by silencing CD74 expression, confirming that
the anti-apoptotic effect of MIF was dependent on CD74/c-
Met complex formation.
In addition to its role in the regulation of cell motility,
cytoskeletal rearrangement and glucose metabolism, the
PI3K/Akt pathway is best known for controlling survival
through functional modulation of various gene products
[45, 46]. Akt is a stress-signaling kinase and key regulator
of energy generating and consuming pathways which
protect cells against hypoxic injury and death. The PI3K/
Akt signaling pathway has been shown to have a major
anti-apoptotic effect in MSCs under hypoxia/SD conditions
[5, 29], and MIF has been shown to activate this pathway
[47]. Our results demonstrated that MIF activated CD74-
dependent c-Met, and this was linked to activation of the
Akt pathway and enhancement of cell survival by MIF.
Silencing Akt attenuated the anti-apoptotic effect of MIF,
suggesting that the protective effect of MIF was dependent
on the PI3K/Akt signaling pathway.
FOXO factors are well known for their role in regulating
stress responses. They can be activated by nutrient depri-
vation, oxidative stress, or DNA damage. In response to
such a wide range of stress stimuli, FOXO factors regulate
a broad variety of cellular mechanisms including DNA
repair, scavenging of ROS, cell cycle progression, apop-
tosis, and metabolism [21, 48, 49]. As previously reported,
in response to hypoxia FOXO3a transcript levels accu-
mulated, suggesting that FOXO3a plays an important role
in the survival response to hypoxic stress [21]. In addition,
FOXO3a directed a protective autophagy program in
haematopoietic stem cells [19]. In our study, we present
evidence that MIF stimulated activation of Forkhead tran-
scription factor FOXO3a to protect MSCs from hypoxia/
SD-induced apoptosis and showed that this protection was
attenuated by silencing of FOXO3a. Furthermore, the ac-
tivity of FOXO3a induced by MIF during hypoxia/SD was
also regulated by the PI3K/Akt pathway, because phospho-
FOXO3a levels increased when treated with MIF, but de-
creased when Akt was silenced. This result agrees with a
previous report showing that phospho-FOXO3a levels in-
creased during hypoxia [21] and suggests that FOXO3a
activity during hypoxia is regulated by the PI3K pathway.
With respect to apoptosis, oxidative stress is in general
associated with induction of cell death [50]. Oxidative
stress is accompanied by ROS generation, an increase in
oxidant enzyme activity, and diminished anti-oxidant en-
zyme activity [51]. Here, we show that hypoxia/SD in-
creased generation of ROS and MDA activity and
decreased activation of SOD in MSCs, while treatment
with MIF reversed these effects, confirming that MIF de-
creased oxidative stress, as shown by previous studies
demonstrating that MIF was an effective anti-oxidant agent
[28, 52]. Silencing of CD74, Akt, or FOXO3a diminished
MIF inhibition of oxidative stress, suggesting that MIF
exerts its anti-oxidative stress effects through a CD74-de-
pendent Akt-FOXO3a signaling pathway.
In conclusion, we propose that MIF promotes MSC
survival under conditions mimicking ischemic myocardi-
um. The results of the present study suggest that MIF
protects MSCs from hypoxia/SD-induced apoptosis via
regulation of oxidative stress in a CD74-dependent Akt-
FOXO3a signaling pathway. These findings highlight po-
tential novel therapeutic strategies for protecting MSCs
from apoptosis, and provide a mechanistic understanding
for the clinical exploitation of MIF and MSCs in cardiac
regeneration therapies.
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